PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Monoclonal antibodies - Market size and forecast 2018-2023 Vaccines - Market size and forecast 2018-2023 Cell and gene therapy - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amgen Inc. Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Merck & Co., Inc. PART 14: APPENDIX Research methodology List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Monoclonal antibodies - Year-over-year growth 2019-2023 (%) Exhibit 21: Vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Vaccines - Year-over-year growth 2019-2023 (%) Exhibit 23: Cell and gene therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Cell and gene therapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by product Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Biologics in the pipeline for cancer Exhibit 42: List of recently approved cancer biologics by the FDA Exhibit 43: Cancer biologics and their biosimilar versions Exhibit 44: Impact of drivers and challenges Exhibit 45: List of collaborations between manufacturers of cancer biologics Exhibit 46: List of predictive biomarkers for cancer Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Amgen Inc. - Vendor overview Exhibit 53: Amgen Inc. - Business segments Exhibit 54: Amgen Inc. - Organizational developments Exhibit 55: Amgen Inc. - Geographic focus Exhibit 56: Amgen Inc. - Key offerings Exhibit 57: Bristol-Myers Squibb Company - Vendor overview Exhibit 58: Bristol-Myers Squibb Company - Business segments Exhibit 59: Bristol-Myers Squibb Company - Organizational developments Exhibit 60: Bristol-Myers Squibb Company - Geographic focus Exhibit 61: Bristol-Myers Squibb Company - Key offerings Exhibit 62: Eli Lilly and Company - Vendor overview Exhibit 63: Eli Lilly and Company - Business segments Exhibit 64: Eli Lilly and Company - Organizational developments Exhibit 65: Eli Lilly and Company - Geographic focus Exhibit 66: Eli Lilly and Company - Segment focus Exhibit 67: Eli Lilly and Company - Key offerings Exhibit 68: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 69: F. Hoffmann-La Roche Ltd - Business segments Exhibit 70: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 71: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 72: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 73: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 74: Merck & Co., Inc. - Vendor overview Exhibit 75: Merck & Co., Inc. - Business segments Exhibit 76: Merck & Co., Inc. - Organizational developments Exhibit 77: Merck & Co., Inc. - Geographic focus Exhibit 78: Merck & Co., Inc. - Segment focus Exhibit 79: Merck & Co., Inc. - Key offerings Exhibit 80: Validation techniques employed for market sizing

Amgen Inc. Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Merck & Co., Inc.